Why is the Pharmaceutical Industry Investing Increasing Amounts in Health Economic Evaluations?
- 1 January 1995
- journal article
- review article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 11 (4) , 750-761
- https://doi.org/10.1017/s0266462300009181
Abstract
Over the last few years, the pharmaceutical industry has financed an increasing number of health economic evaluations. The purpose of this article is to describe how and why the pharmaceutical industry is applying health economic evaluations. Seven different fields of application are identified, and the varying reasons for use are discussed.Keywords
This publication has 20 references indexed in Scilit:
- The Journal's Policy on Cost-Effectiveness AnalysesNew England Journal of Medicine, 1994
- Applying the Australian Guidelines for the Reimbursement of PharmaceuticalsPharmacoEconomics, 1994
- Australian Pharmaceutical Pricing GuidelinesPharmacoEconomics, 1994
- Something rotten in the state of clinical and economic evaluations?Health Economics, 1994
- Strategic Use of Pharmacoeconomic Research in Early Drug Development and Global PricingPharmacoEconomics, 1993
- Guidelines for Economic Analysis of Pharmaceutical ProductsPharmacoEconomics, 1993
- Regulation of the Pharmaceutical IndustryPharmacoEconomics, 1992
- Australian Guidelines for Cost-Effectiveness Studies of PharmaceuticalsPharmacoEconomics, 1992
- Economic Analysis as an Aid to Subsidisation DecisionsPharmacoEconomics, 1992
- Cost of innovation in the pharmaceutical industryJournal of Health Economics, 1991